Maria Liljefors

Publications
CV
Public outreach and news

Articles

Article: LANCET GASTROENTEROLOGY & HEPATOLOGY. 2024;9(3):205-217

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ; Bratlie SO; Andersson B; Angelsen J-H; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K; Nordic Pancreatic Cancer Trial-1 study group
Article: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7196-7205

Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study.

Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Article: BMC CANCER. 2023;23(1):949

Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer.

Crespo-Bravo M; Thorlacius-Ussing J; Nissen NI; Pedersen RS; Boisen MK; Liljefors M; Johansen AZ; Johansen JS; Karsdal MA; Willumsen N
Article: WORLD JOURNAL OF SURGICAL ONCOLOGY. 2023;21(1):286

Gallbladder cancer mimicking perihilar cholangiocarcinoma-considerable rate of postoperative reclassification with implications for prognosis.

Nooijen LE; Gustafsson-Liljefors M; Erdmann JI; D'Souza MA; Gilg S; Villard C; Jansson H
Article: ANNALS OF SURGICAL ONCOLOGY. 2023;30(7):4433-4441

Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study.

Graversen M; Rouvelas I; Ainsworth AP; Bjarnesen AP; Detlefsen S; Ellebaek SB; Fristrup CW; Liljefors MG; Lundell L; Nilsson M; Pfeiffer P; Tarpgaard LS; Tsekrekos A; Mortensen MB
Article: PANCREATOLOGY. 2022;22(5):598-607

Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.

Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr J-M; Sparrelid E
Article: SCIENTIFIC REPORTS. 2021;11(1):865

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.

Nissen NI; Kehlet S; Boisen MK; Liljefors M; Jensen C; Johansen AZ; Johansen JS; Erler JT; Karsdal M; Mortensen JH; Høye A; Willumsen N
Article: CANCERS. 2019;11(9):E1326-1326

Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort.

Kordes M; Yu J; Malgerud O; Gustafsson Liljefors M; Löhr J-M
Article: MOLECULAR ONCOLOGY. 2017;11(10):1413-1429

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.

Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Article: PLOS ONE. 2017;12(1):e0169736

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

Ullenhag GJ; Mozaffari F; Broberg M; Mellstedt H; Liljefors M
Article: PLOS ONE. 2015;10(4):e0121197

A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.

Ullenhag GJ; Rossmann E; Liljefors M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

Staff C; Mozaffari F; Frödin J-E; Mellstedt H; Liljefors M
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.

Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frödin J-E; Wahrén B; Mellstedt H; Ullenhag GJ
Article: VACCINE. 2011;29(39):6817-6822

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.

Staff C; Mozaffari F; Haller BK; Wahren B; Liljefors M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(6):1599-1606

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

Wang B; Kokhaei P; Mellstedt H; Liljefors M
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2008;130(3):375-381

Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis.

Rubio CA; Orrego A; Höög A; Porwitz A; Petersson F; Elmberger G; Glaessgen A; Eriksson E; Kanter L; Jaremko G; Egevad L; Laforga J; Liljefors M; Löfdahl B; Norman P; Larsson O; Wanat R; Wejde J; Zickert P; Björk J; Caini S; Palli D; Nesi G
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(3):379-388

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.

Liljefors M; Nilsson B; Mellstedt H; Frödin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin J-E
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383

Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients.

Shetye JD; Liljefors ML; Emdin SO; Frödin J-E; Strigård K; Mellstedt HT; Porwit A
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.

Liljefors M; Nilsson B; Hjelm Skog A-L; Ragnhammar P; Mellstedt H; Frödin J-E
Article: HYBRIDOMA. 2002;21(2):99-101

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Frödin J-E; Fagerberg J; Hjelm Skog A-L; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;48(8):463-470

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1999;5(6):1353-1361

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.

Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.

Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1996;42(2):81-87

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.

Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Show more

All other publications

Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7257-7258

ASO Visual Abstract: Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study.

Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7251-7252

ASO Author Reflections: The Impact of Minimally Invasive Surgery on the Completion Rate of the Perioperative Chemotherapy Protocol in Gastric Cancer.

Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(7):4442-4443

ASO Visual Abstract: Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence: The PIPAC-OPC4 Study.

Graversen M; Rouvelas I; Ainsworth AP; Bjarnesen AP; Detlefsen S; Ellebaek SB; Fristrup CW; Liljefors MG; Lundell L; Nilsson M; Pfeiffer P; Tarpgaard LS; Tsekrekos A; Mortensen MB
Editorial comment: JCO PRECISION ONCOLOGY. 2021;5:974-980

Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma.

Kordes M; Tamborero D; Lagerstedt-Robinson K; Yachnin J; Rosenquist R; Löhr J-M; Gustafsson Liljefors M
Meeting abstract: ANNALS OF ONCOLOGY. 2018;29:vi31

Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001

Kordes M; Lohr M; Malgerud L; Kaduthanam S; Frodin J-E; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel R; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Engstrand L; Brock S; Gustafsson-Liljefors M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16243

Palliative treatment of pancreatic adenocarcinoma in a real-world setting.

Kordes M; Malgerud O; Karimi M; Frodin J-E; Liljefors MG; Loehr M
Published paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261

Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma.

Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.

Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A

Employments

Affiliated to Research, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2022-2024

Degrees and Education

Docent, Karolinska Institutet, 2017
Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2005
University Medical Degree, Karolinska Institutet, 1992

Supervisor

Cecilia Merk, 2022

Articles

All other publications

Employments

Degrees and Education

Supervisor

News from KI

Events from KI